share_log

個別銘柄のひと口情報

Individual stock information.

Kabushiki Shimbun ·  Mar 19 07:24

DWTI<4576.T>

A sharp rebound. On the 18th, the company announced that it received notification from its licensee, Kowa (Nagoya City), that administration to subjects in a Global Phase III clinical trial for the Rhokinase inhibitor "Ripasi-1 hydrochloride hydrate" eye drops "K-321" has been completed. Follow-up observations of the subjects are scheduled to be completed by the end of October.

Trenders<6069.T>

A rebound. Plans to make zenplus (Chuo-ku, Tokyo), which handles planning, production, and operation of various events, a subsidiary. In the future, the company aims to provide more three-dimensional marketing solutions by combining its strength in SNS (Social...

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 242

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.